Damien McDevitt - 29 Oct 2026 Form 3 Insider Report for Aspen Neuroscience, Inc.

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
29 Oct 2026, 20:04:36 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: /s/ Jeffrey L. Boerneke, as Attorney-in-Fact
Filing notes and source

Key filing fact

Damien McDevitt filed Form 3 for Aspen Neuroscience, Inc. on 29 Oct 2026.

Key facts

  • This page summarizes Damien McDevitt's Form 3 filing for Aspen Neuroscience, Inc..
  • 0 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 29 Oct 2026, 20:04.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742277 Primary reporting owner

McDevitt Damien

Relationship
Exhibit 24 - Power of Attorney President and Chief Executive Officer, Director
Address
10835 ROAD TO THE CURE, SUITE 100, SAN DIEGO
Signature
By: /s/ Jeffrey L. Boerneke, as Attorney-in-Fact
Signature date
29 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
485,751
Date
29 Oct 2026
Ownership
See Footnote 1.
Footnotes
F1
No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
25,299
Date
29 Oct 2026
Ownership
See Footnote 2.
Footnotes
F2
No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
25,299
Date
29 Oct 2026
Ownership
See Footnote 3.
Footnotes
F3
No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
25,299
Date
29 Oct 2026
Ownership
See Footnote 4.
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
29 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
196,820
Exercise price
$8.70
Footnotes
F5
No ticker holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
29 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
387,063
Exercise price
$5.74
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Shares of Common Stock held by Damien McDevitt and Pamela Marnell-McDevitt, Co-trustees of the Marnell-McDevitt Family Trust dated May 2, 2019, of which 93,607 shares remain subject to performance-based vesting conditions and to repurchase by the Issuer if such conditions are not met or upon termination of the Reporting Person's service.

Footnote F2

Shares of Common Stock held by Finn McDevitt, Trustee of the Finn McDevitt 2025 Irrevocable Trust.

Footnote F3

Shares of Common Stock held by Aran McDevitt, Trustee of the Aran McDevitt 2025 Irrevocable Trust.

Footnote F4

Shares of Common Stock held by Conor McDevitt, Trustee of the Conor McDevitt 2025 Irrevocable Trust.

Footnote F5

The option was granted on December 16, 2024. The option is fully vested and exercisable.

Footnote F6

The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In August 2026, the vesting schedule was amended such that the unvested shares subject to the option as of July 20, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.

SEC remarks

Exhibit 24 - Power of Attorney President and Chief Executive Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .